Calcium Dysregulation in Progressive Supranuclear Palsy

Calcium Dysregulation in Progressive Supranuclear Palsy

Overview

Calcium (Ca²⁺) homeostasis is essential for neuronal survival, synaptic transmission, and cellular signaling. Progressive Supranuclear Palsy (PSP), a 4-repeat tauopathy characterized by progressive postural instability, supranuclear gaze palsy, and cognitive decline, involves significant calcium dysregulation that contributes to neuronal vulnerability, tau pathology, and progressive neurodegeneration [1][2]. While calcium dysregulation has been extensively studied in Alzheimer's disease (AD) and Parkinson's disease (PD), emerging evidence specifically links calcium mishandling to the selective vulnerability of brainstem nuclei, basal ganglia, and cortical neurons in PSP [3]. [@pchitskaya2023]

The precise mechanisms underlying calcium dysregulation in PSP involve multiple interconnected pathways: voltage-gated calcium channel (VGCC) alterations, impaired mitochondrial calcium buffering, endoplasmic reticulum (ER) stress, store-operated calcium entry (SOCE) dysfunction, and excitotoxic mechanisms. These disturbances create a vicious cycle that accelerates tau hyperphosphorylation, aggregation, and propagation while simultaneously promoting neuronal apoptosis. [@choi2024]

Calcium Signaling Pathways in PSP

```mermaid
flowchart TD
subgraph Extracellular
A["Extracellular Ca2+"]
end

subgraph Membrane
B["Voltage-Gated<br/>Ca2+ Channels"]
C["L-type Ca2+ Channel"]
D["P/Q-type Ca2+ Channel"]
E["T-type Ca2+ Channel"]
end

Calcium Dysregulation in Progressive Supranuclear Palsy

Overview

Calcium (Ca²⁺) homeostasis is essential for neuronal survival, synaptic transmission, and cellular signaling. Progressive Supranuclear Palsy (PSP), a 4-repeat tauopathy characterized by progressive postural instability, supranuclear gaze palsy, and cognitive decline, involves significant calcium dysregulation that contributes to neuronal vulnerability, tau pathology, and progressive neurodegeneration [1][2]. While calcium dysregulation has been extensively studied in Alzheimer's disease (AD) and Parkinson's disease (PD), emerging evidence specifically links calcium mishandling to the selective vulnerability of brainstem nuclei, basal ganglia, and cortical neurons in PSP [3]. [@pchitskaya2023]

The precise mechanisms underlying calcium dysregulation in PSP involve multiple interconnected pathways: voltage-gated calcium channel (VGCC) alterations, impaired mitochondrial calcium buffering, endoplasmic reticulum (ER) stress, store-operated calcium entry (SOCE) dysfunction, and excitotoxic mechanisms. These disturbances create a vicious cycle that accelerates tau hyperphosphorylation, aggregation, and propagation while simultaneously promoting neuronal apoptosis. [@choi2024]

Calcium Signaling Pathways in PSP

Voltage-Gated Calcium Channel Alterations

L-Type Calcium Channels

L-type voltage-gated calcium channels (Cav1.2, encoded by [CACNA1C](/genes/cacna1c)) are prominently expressed in neurons of the substantia nigra, basal ganglia, and brainstem nuclei—regions particularly affected in PSP [4]. Post-mortem studies of PSP brain tissue demonstrate increased L-type channel expression and enhanced calcium influx in vulnerable neuronal populations. This upregulation appears to be a compensatory response to cellular stress, but paradoxically contributes to calcium overload and subsequent neurotoxicity [5]. [@hoozemans2022]

The dysregulation of L-type channels in PSP shares similarities with findings in PD, where Cav1.3 (encoded by [CACNA1D](/genes/cacna1d)) channels have been extensively studied. However, PSP demonstrates a distinct pattern with preferential involvement of Cav1.2-containing channels in brainstem motor nuclei [6]. [@bezprozvanny2023]

P/Q-Type and N-Type Channels

P/Q-type calcium channels (Cav2.1, encoded by [CACNA1A](/genes/cacna1a)) and N-type channels (Cav2.2, encoded by [CACNA1B](/genes/cacna1b)) regulate neurotransmitter release at synaptic terminals. In PSP, these channels exhibit altered phosphorylation states and trafficking, leading to dysregulated synaptic calcium dynamics. The resulting imbalance between excitatory and inhibitory neurotransmission contributes to the characteristic movement disorders observed in PSP, including bradykinesia, rigidity, and supranuclear gaze palsy [7]. [@surmeier2024]

T-Type Calcium Channels

T-type calcium channels (Cav3.1, Cav3.2, Cav3.3) generate low-threshold calcium spikes important for neuronal excitability. Studies in PSP models demonstrate enhanced T-type channel activity, particularly in subthalamic nucleus neurons. This hyperactivity contributes to abnormal burst firing patterns and network oscillations that underlie the parkinsonian features of PSP [8].

Mitochondrial Calcium Handling in PSP

Mitochondrial Calcium Overload

Mitochondria serve as critical calcium buffers, sequestering excess cytosolic calcium during periods of elevated influx. In PSP, multiple factors converge to overwhelm mitochondrial calcium handling capacity:

• Enhanced calcium influx through dysregulated VGCCs delivers excessive calcium to the mitochondrial matrix
• Impaired mitochondrial dynamics—fusion/fission imbalances—reduce the ability to distribute calcium load across the mitochondrial network
• Defective calcium uniporter (MCU) complex function limits calcium uptake capacity

The Mitochondria-Associated ER Membrane (MAM)

The mitochondria-associated ER membrane (MAM) is a specialized subdomain where ER and mitochondria form tight contacts, enabling direct calcium transfer. In PSP, tau pathology disrupts MAM integrity, leading to abnormal calcium transfer between these organelles. This disruption creates a bidirectional pathogenic loop: tau accumulation disrupts calcium homeostasis, while calcium dysregulation promotes further tau pathology [9][10].

The [Na⁺/Ca²⁺ Exchanger (NCX)](/proteins/ncx-protein) and mitochondrial calcium exchangers like NCLX play crucial roles in mitochondrial calcium efflux. Dysfunction of these exchangers in PSP contributes to mitochondrial calcium overload and subsequent bioenergetic failure [11].

Mitochondrial Calcium-Induced Apoptosis

Excessive mitochondrial calcium accumulation triggers the mitochondrial permeability transition pore (mPTP), leading to:

• Cytochrome c release into the cytosol
• Caspase-9 and caspase-3 activation
• Apoptotic neuronal death

Endoplasmic Reticulum Stress and Calcium

ER Calcium Depletion

The endoplasmic reticulum (ER) serves as the primary intracellular calcium reservoir. In PSP, ER calcium stores become progressively depleted through multiple mechanisms:

Unfolded Protein Response (UPR)

ER calcium depletion triggers the unfolded protein response (UPR), a compensatory mechanism that initially attempts to restore ER homeostasis but becomes maladaptive when prolonged. In PSP, chronic UPR activation leads to:

• Pro-apoptotic signaling through CHOP
• Inhibition of protein synthesis
• Further disruption of calcium homeostasis

Store-Operated Calcium Entry (SOCE)

STIM1 and Orai1 Dysfunction

When ER calcium stores are depleted, store-operated calcium entry (SOCE) is activated through the STIM1-Orai1 mechanism. [STIM1](/proteins/stim1-protein) senses ER calcium depletion and activates plasma membrane Orai1 channels, allowing extracellular calcium influx.

In PSP, chronic ER calcium depletion leads to sustained SOCE activation. While initially protective, prolonged SOCE contributes to:

• Cytosolic calcium overload
• Neuroinflammation through NFAT activation
• Accelerated tau pathology

Excitotoxicity in PSP

Glutamate Receptor Dysregulation

Excitotoxicity—excessive glutamate receptor activation—represents a major consequence of calcium dysregulation in PSP. The excessive calcium influx through VGCCs and SOCE primes neurons for glutamate-induced excitotoxicity:

• NMDA receptor overactivation leads to excessive calcium influx
• AMPA receptor dysfunction alters excitatory neurotransmission
• Metabotropic glutamate receptors contribute to intracellular signaling disturbances

Comparison to Other Tauopathies

Excitotoxicity in PSP differs from that observed in corticobasal syndrome (CBS) in several key aspects:

• PSP shows preferential vulnerability of brainstem nuclei
• CBS demonstrates more prominent cortical involvement
• Both share 4R-tau pathology but calcium dysregulation patterns differ

Comparison to Alzheimer's Disease and Parkinson's Disease

AD vs PSP Calcium Dysregulation

| Feature | Alzheimer's Disease | PSP |
|---------|-------------------|-----|
| Primary calcium dysregulation site | Cortical neurons, hippocampus | Brainstem nuclei, basal ganglia |
| Channel focus | L-type, NMDA receptors | P/Q-type, T-type, L-type |
| ER stress | Prominent (Aβ toxicity) | Moderate |
| Mitochondrial dysfunction | Severe | Severe |
| Calcium buffering proteins | Calbindin reduction | Parvalbumin alterations |

While [Calcium Dysregulation in Alzheimer's Disease](/mechanisms/calcium-dysregulation-ad) prominently features amyloid-β-mediated toxicity and hippocampal vulnerability, PSP calcium dysregulation is more closely linked to tau pathology and brainstem-selective vulnerability [14].

PD vs PSP Calcium Dysregulation

| Feature | Parkinson's Disease | PSP |
|---------|---------------------|-----|
| Primary affected region | Substantia nigra pars compacta | Substantia nigra pars reticulata, brainstem |
| Channel focus | L-type (Cav1.3) | Multiple VGCCs |
| Mitochondrial pathway | Complex I deficiency | Multiple complexes |
| Calcium-protein interactions | α-Synuclein | Tau protein |

The [Calcium Signaling Dysregulation in Parkinson's Disease](/mechanisms/calcium-dysregulation-parkinsons) page provides comprehensive PD-specific mechanisms. Notably, both PSP and PD involve substantia nigra vulnerability, but the pattern of calcium dysregulation differs in channel subtype involvement and regional distribution [15].

Therapeutic Implications

Calcium Channel Modulators

Given the central role of calcium dysregulation in PSP pathogenesis, calcium channel modulators represent rational therapeutic targets:

• L-type channel blockers (e.g., isradipine) have shown promise in PD models and may benefit PSP
• P/Q-type channel modulators could normalize synaptic calcium dynamics
• T-type channel antagonists may reduce abnormal neuronal firing

Mitochondrial-Targeted Therapies

Drugs targeting mitochondrial calcium handling show potential for PSP:

• MCU inhibitors to prevent mitochondrial calcium overload
• NCLX activators to enhance mitochondrial calcium efflux
• mPTP blockers to prevent cytochrome c release

ER Stress Modulators

Reducing ER calcium depletion and UPR activation:

• SERCA activators to restore ER calcium stores
• IP₃ receptor antagonists to reduce ER calcium leak
• Chemical chaperones to alleviate UPR

Summary

Calcium dysregulation in PSP represents a complex, multifactorial pathology involving:

These mechanisms create a self-perpetuating cycle that accelerates neurodegeneration in PSP-affected brain regions. The comparison with AD and PD reveals both shared features and disease-specific patterns, highlighting the importance of understanding calcium dysregulation as a therapeutic target for PSP and related neurodegenerative disorders.

See Also

• [CACNA1C](/genes/cacna1c)
• [CACNA1D](/genes/cacna1d)
• [CACNA1A](/genes/cacna1a)
• [CACNA1B](/genes/cacna1b)
• [Na⁺/Ca²⁺ Exchanger (NCX)](/proteins/ncx-protein)
• [SERCA](/proteins/serca-protein)
• [IP₃ Receptor](/proteins/ip3r-protein)
• [STIM1](/proteins/stim1-protein)
• [CBS vs PSP: Comparative Mechanism Analysis](/mechanisms/cbs-vs-psp-comparison)
• [Calcium Dysregulation in Alzheimer's Disease](/mechanisms/calcium-dysregulation-ad)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Pathway Diagram

The following diagram shows the key molecular relationships involving Calcium Dysregulation in Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis: